Sufficient trial size to inform clinical practice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 38, 2016, Pages 10518-10523

  Manski, Charles F ^a   Tetenov, Aleksey ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c Center for Research on Pensions and Welfare Policies Collegio Carlo Alberto   (Italy)

Author keywords

Clinical trials; Medical decision making; Near optimality; Sample size

Indexed keywords

ARTICLE; BAYES THEOREM; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DECISION THEORY; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; PRIORITY JOURNAL; SAMPLE SIZE; STUDY DESIGN; TREATMENT RESPONSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

BAYES THEOREM; BIOMEDICAL RESEARCH; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE;

EID: 84988681800     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1612174113     Document Type: Article

References (35)

1. Ioannidis JP (2005) Why most published research findings are false. PLoS Med 2(8):e124.
2. Wasserstein R, Lazar N (2016) The ASA's statement on p-values: Context, process, and purpose. Am Stat 70(2):129-133.
3. US Food and Drug Administration (1996) Statistical Guidance for Clinical Trials of Nondiagnostic Medical Devices. Available at www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm106757.htm. Accessed August 24, 2016.
4. International Conference on Harmonisation (1999) ICH E9 Expert Working Group. Statistical principles for clinical trials: ICH harmonized tripartite guideline. Stat Med 18(15):1905-1942.
5. Halpern SD, Karlawish JH, Berlin JA (2002) The continuing unethical conduct of underpowered clinical trials. JAMA 288(3):358-362.
6. Altman DG (1980) Statistics and ethics in medical research: III. How large a sample? BMJ 281(6251):1336-1338.
7. Dunnett C (1955) A multiple comparison procedure for comparing several treatments with a control. JASA 50(272):1096-1121.
8. Cook R, Farewell V (1996) Multiplicity considerations in the design and analysis of clinical trials. J R Stat Soc Ser A 159(1):93-110.
9. Spiegelhalter D, Freedman L, Parmar M (1994) Bayesian approaches to randomized trials (with discussion). J R Stat Soc Ser A 157(3):357-416.
10. Spiegelhalter D (2004) Incorporating Bayesian ideas into health-care evaluation. Stat Sci 19(1):156-174.
11. Claxton K, Posnett J (1996) An economic approach to clinical trial design and research priority-setting. Health Econ 5(6):513-524.
12. Meltzer D (2001) Addressing uncertainty in medical cost-effectiveness analysis implications of expected utility maximization for methods to perform sensitivity analysis and the use of cost-effectiveness analysis to set priorities for medical research. J Health Econ 20(1):109-129.
13. Cheng Y, Su F, Berry D (2003) Choosing sample size for a clinical trial using decision analysis. Biometrika 90(4):923-936.
14. Berry D (2004) Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 19(1):175-187.
15. Savage L (1951) The theory of statistical decision. JASA 46(253):55-67.
16. Wald A (1950) Statistical Decision Functions (Wiley, New York).
17. Ferguson T (1967) Mathematical Statistics: A Decision Theoretic Approach (Academic, New York).
18. Berger J (1985) Statistical Decision Theory and Bayesian Analysis (Springer, New York), 2nd Ed.
19. Manski C (2004) Statistical treatment rules for heterogeneous populations. Econometrica 72(4):1221-1246.
20. Manski C (2005) Social Choice with Partial Knowledge of Treatment Response (Princeton Univ Press, Princeton).
21. Manski C (2007) Minimax-regret treatment choice with missing outcome data. J Econom 139(1):105-115.
22. Manski C, Tetenov A (2007) Admissible treatment rules for a risk-averse planner with experimental data on an innovation. J Stat Plan 137(6):1998-2010.
23. Hirano K, Porter J (2009) Asymptotics for statistical treatment rules. Econometrica 77(5):1683-1701.
24. Schlag K (2006) ELEVEN - Tests needed for a recommendation, EUI Working Paper ECO no. 2006/2 (European University Institute, Florence, Italy). Available at cadmus.eui.eu//handle/1814/3937. Accessed August 24, 2016.
25. Stoye J (2009) Minimax regret treatment choice with finite samples. J Econom 151(1):70-81.
26. Stoye J (2012) Minimax regret treatment choice with covariates or with limited validity of experiments. J Econom 166(1):138-156.
27. Tetenov A (2012) Statistical treatment choice based on asymmetric minimax regret criteria. J Econom 166(1):157-165.
28. Hróbjartsson A, Gøtzsche PC (2001) Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344(21):1594-1602.
29. Lichtenberg P, Heresco-Levy U, Nitzan U (2004) The ethics of the placebo in clinical practice. J Med Ethics 30(6):551-554.
30. Sedgwick P (2014) Clinical significance versus statistical significance. BMJ 348:g2130.
31. Materson BJ, et al.; The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents (1993) Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 328(13):914-921.
32. Fleiss J (1973) Statistical Methods for Rates and Proportions Wiley, New York).
33. Hoeffding W (1963) Probability inequalities for sums of bounded random variables. JASA 58(301):13-30.
34. Lugosi G (2002) Pattern classification and learning theory. Principles of Nonparametric Learning, ed Gyorfi L (Springer, Vienna), pp 1-56.
35. Bentkus V (2004) On Hoeffding's inequalities. Ann Probab 32(2):1650-1673.